Keywords: daclizumab, impresses, ph, ii, ms, study, biogen

Daclizumab impresses in Ph II MS study

Article | 19 March 2007

Print This

Biogen Idec and fellow USA-based PDL BioPharma say that data from an ongoing trial of the co-developed monoclonal antibody, daclizumab, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in